PRTG — Portage Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $20.76m
- $18.38m
Annual cashflow statement for Portage Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.2 | -19.2 | -105 | -75.4 | -6.78 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 11.2 | 8.47 | 110 | 70.6 | -0.237 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.744 | -0.461 | -0.01 | 0.982 | 1.52 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.28 | -6.76 | -12.1 | -14.3 | -5.46 |
| Capital Expenditures | — | — | -0.003 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.86 | 0 | -0.614 | 2.81 | 0 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.86 | 0 | -0.617 | 2.81 | 0 |
| Financing Cash Flow Items | -1.25 | -1.85 | -1.1 | 5.32 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.76 | 27.3 | -0.117 | 5.97 | 2.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.382 | 20.6 | -12.8 | -5.52 | -3.36 |